Adicet Bio has dosed the first systemic sclerosis (SSc) subject in the Phase I trial’s second cohort evaluating ADI-001.

Memo Therapeutics will discuss the Phase III trial design for potravitug in kidney transplant infection with regulators by the end of 2025.

Vir Biotechnology has dosed the first subject in the non-randomised Phase I trial to assess VIR-5525, the investigational dual-masked TCE.

Windward Bio has launched the Phase II POLARIS trial of the recombinant, fully human monoclonal antibody, WIN378, in individuals with asthma.

ANI Pharmaceuticals has disclosed the outcomes of its NEW DAY trial, assessing Iluvien 0.19mg, in people with diabetic macular oedema.

Monte Rosa Therapeutics has dosed the first participants in the Phase I trial of the NEK7-directed molecular glue degrader (MGD), MRT-8102.

AstraZeneca's Tagrisso combined with pemetrexed and platinum-based chemotherapy has shown improvement in overall survival (OS).

The trail demonstrates that a swallowable, low-pill, non-absorbed iron polymer can match or exceed sevelamer in phosphate control.

Ocugen has dosed the first subject in its Phase II/III GARDian3 trial of modifier gene therapy candidate, OCU410ST.

Industry experts have provided insight into how oncology clinical trials can be designed for success from the outset and rendered as patient-centric as possible.

Bristol Myers Squibb (BMS) has revealed that its Phase III trial assessing Reblozyl with JAKi therapy did not meet its primary goal.

Sarepta CEO Doug Ingram said it is important the company maintains a “positive working relationship” with the FDA.